

FOR IMMEDIATE RELEASE

CONTACT:

Eric Button
BioMarker Group
(704) 707-3759
ebutton@biomarkergroup.com

All Major National Reference Laboratories Now Offer New GlycoMark Diabetes Blood Test to Complement Hemoglobin A1c Testing in Patients with Diabetes

Chicago, Illinois and Kannapolis, North Carolina - June 22, 2007 - The GlycoMark diabetes blood test is now available at major clinical reference laboratories nationwide, including Quest Diagnostics, LabCorp, Esoterix, Specialty Laboratories, and Mayo Medical Laboratories. This announcement was made at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.

“This new blood test for diabetes has the potential to become an integral part of diabetes test offerings, providing complementary information to hemoglobin A1c (A1C), a key indicator for diabetes control, by providing a more specific measure of after-meal glucose levels and short-term glycemic control,” said John Buse, M.D., Ph.D., a professor of medicine and chief of the Division of Endocrinology at the University of North Carolina School of Medicine at Chapel Hill.

In a recent study completed by Kathleen Dungan, M.D. and John Buse, M.D., Ph.D. at the University of North Carolina and Steve Wittlin, M.D. at the University of Rochester and published in the American Diabetes Association *Diabetes Care* journal it was shown that the GlycoMark 1,5-AG test was a better measure of after-meal glucose levels compared to standard tests for diabetes. This is important as a growing body of evidence suggests that controlling after-meal glucose levels play a significant role in achieving optimal glycemic control and reducing the burden of cardiovascular complications, the leading cause of death in patients with diabetes.

In recent clinical studies using new agents to target after-meal glucose levels, GlycoMark was reported to respond more sensitively to changes in after-meal glucose levels than A1C ([see associated press release for more details on new studies](#)). These are important findings as GlycoMark revealed underlying treatment effects of after-meal glucose control which were not readily apparent by A1C measurements – giving physicians the ability to make necessary adjustments to these medications.

“We are pleased that GlycoMark is now being offered by all major clinical reference laboratories in the U.S.,” said Eric Button, CEO of the BioMarker Group. Button added, “The weight of scientific evidence supporting the use of GlycoMark as a companion diagnostic for therapeutic agents targeting postprandial hyperglycemia continues to grow. More and more reference laboratories, both in the U.S. and internationally, are recognizing the surge of momentum behind the GlycoMark test.”

About GlycoMark

GlycoMark is an FDA approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5-AG) in blood. Multiple published studies in peer-reviewed journals have shown that the 1,5-AG test is a

specific index of postprandial hyperglycemia (elevated after-meal glucose levels) and short-term glycemic control – providing a useful complement to A1C testing. GlycoMark is being used in clinical practices nationwide and is available at major clinical reference laboratories including Quest Diagnostics, LabCorp, Esoterix, Mayo Medical Laboratories, and Specialty Laboratories. The test is also available at most major contract research organizations for pharmaceutical research studies.

GlycoMark is being commercialized by a partnership between Toyota Tsusho America (New York, NY), Nippon Kayaku (Tokyo, Japan) and the BioMarker Group (Kannapolis, NC). GlycoMark activities are centered in the North Carolina Research Campus in Kannapolis, North Carolina, a 350-acre life sciences hub started by billionaire David H. Murdock.

More information about GlycoMark may be found at www.glycomark.com.